Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOstolin, Thais Lopes Valentim Di Paschoale-
dc.contributor.authorGusmão, Miriã Rodrigues-
dc.contributor.authorMathias, Fernando Augusto Siqueira-
dc.contributor.authorCardoso, Jamille Mirelle de Oliveira-
dc.contributor.authorRoatt, Bruno Mendes-
dc.contributor.authorSoares, Rodrigo Dian de Oliveira Aguiar-
dc.contributor.authorRuiz, Jeronimo Conceição-
dc.contributor.authorResende, Daniela de Melo-
dc.contributor.authorBrito, Rory Cristiane Fortes de-
dc.contributor.authorReis, Alexandre Barbosa-
dc.identifier.citationOSTOLIN, T. L. V. D. P. et al. A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice. Vaccine, v. 39, p. 2755-2763, 2021. Disponível em: <>. Acesso em: 10 jun. 2021.pt_BR
dc.description.abstractIn Brazil, canine visceral leishmaniasis is an important public health problem due to its alarming growth. The high prevalence of infected dogs reinforces the need for a vaccine for use in prophylactic vaccination campaigns. In the present study, we evaluate the immunogenicity and protection of the best dose of Chimera A selected through the screening of cytokines production important in disease. BALB/c mice were vaccinated subcutaneously with three doses and challenged intravenously with 1 107 L. infantum promastigotes. Spleen samples were collected to assess the intracellular cytokine profile production, T cell proliferation and parasite load. At first, three different doses of Chimera A (5 lg, 10 lg and 20 lg) were evaluated through the production of IFN-c and IL-10 cytokines. Since the dose of 20 lg showed the best results, it was chosen to continue the study. Secondarily, Chimera A at dose of 20 lg was formulated with Saponin plus Monophosphoryl lipid A. Vaccination with Chimera A alone and formulated with SM adjuvant system was able to increase the percentage of the proliferation of specific T lymphocytes and stimulated a Th1 response with increased levels of IFN-c, TNF-a and IL-2, and decreased of IL-4 and IL-10. The vaccine efficacy through real-time PCR demonstrated a reduction in the splenic parasite load in animals that received Chimera A formulated with the SM adjuvant system (92%). Additionally, we observed increased levels of nitric oxide in stimulated-culture supernatants. The Chimera A formulated with the SM adjuvant system was potentially immunogenic, being able to induce immunoprotective mechanisms and reduce parasite load. Therefore, the use of T-cell multi-epitope vaccine is promising against visceral leishmaniasis.pt_BR
dc.subjectLeishmania infantumpt_BR
dc.subjectMulti-epitope vaccinept_BR
dc.subjectImmune responsept_BR
dc.titleA chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice.pt_BR
dc.typeArtigo publicado em periodicopt_BR
Appears in Collections:DEACL - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
  Restricted Access
1,31 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.